EFFICACY OF SUPRACHOROIDAL TRIAMCINOLONE ACETONIDE INJECTION IN THE TREATMENT OF RESISTANT DIABETIC MACULAR EDEMA

This study aimed to assess the efficacy of suprachoroidal TA injection for treating diabetic macular edema resistant anti-VEGF agents. A prospective was conducted in Ophthalmology Department Service Hospital, Lahore, from December 2020 2021. total 60 patients were included study. Suprachoroidal 4 mg/0.1 mL given after diagnosing DME. The administered every 3 months during follow-up period (12 months) if intraretinal cysts, or subretinal fluid persisted and CMT remained > 250 µm. primary endpoint reduction BCVA improvement 12 injection. secondary assessing safety mean at baseline 478.6±170.1 µm, months, it 230.1 ± 47.5 decrease statistically significant (P< .001). 1.194±0.1; 0.75±0.2 (P<.001). After one month injection, IOP reached maximum value (13.2±0.4 mmHg) compared (12.32±0.1mmHg). It gradually declined with use topical beta blockers 3rd month, glaucoma surgery not needed any patient. effectively treats DMA leads SCVA reduction.